OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review)
Jingyi He, Zhengrong Huang, Linzhi Han, et al.
International Journal of Oncology (2021) Vol. 59, Iss. 5
Open Access | Times Cited: 200
Jingyi He, Zhengrong Huang, Linzhi Han, et al.
International Journal of Oncology (2021) Vol. 59, Iss. 5
Open Access | Times Cited: 200
Showing 26-50 of 200 citing articles:
Epithelial–mesenchymal transition to Mitigate Age-Related Progression in Lung Cancer
Riya Thapa, Saurabh Gupta, Gaurav Gupta, et al.
Ageing Research Reviews (2024) Vol. 102, pp. 102576-102576
Closed Access | Times Cited: 5
Riya Thapa, Saurabh Gupta, Gaurav Gupta, et al.
Ageing Research Reviews (2024) Vol. 102, pp. 102576-102576
Closed Access | Times Cited: 5
Comprehensive multi-omics analysis of the m7G in pan-cancer from the perspective of predictive, preventive, and personalized medicine
Xiaoliang Huang, Zuyuan Chen, Xiaoyun Xiang, et al.
The EPMA Journal (2022) Vol. 13, Iss. 4, pp. 671-697
Closed Access | Times Cited: 20
Xiaoliang Huang, Zuyuan Chen, Xiaoyun Xiang, et al.
The EPMA Journal (2022) Vol. 13, Iss. 4, pp. 671-697
Closed Access | Times Cited: 20
2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation
Tomoaki Sasaki, Hirofumi Kuno, Takashi Hiyama, et al.
Radiographics (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 4
Tomoaki Sasaki, Hirofumi Kuno, Takashi Hiyama, et al.
Radiographics (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 4
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
Mai Suzuki, Ken Uchibori, Tomoko Oh‐hara, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
Mai Suzuki, Ken Uchibori, Tomoko Oh‐hara, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 4
A radiobiological perspective on radioresistance or/and radiosensitivity of head and neck squamous cell carcinoma
Chenxi Li, Xiaorong Tan, Wei Wei, et al.
Reports of Practical Oncology & Radiotherapy (2024) Vol. 28, Iss. 6, pp. 809-822
Open Access | Times Cited: 4
Chenxi Li, Xiaorong Tan, Wei Wei, et al.
Reports of Practical Oncology & Radiotherapy (2024) Vol. 28, Iss. 6, pp. 809-822
Open Access | Times Cited: 4
Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer
Yuan Zhang, Jinheng Qian, Yanneng Fu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 7, pp. 167447-167447
Closed Access | Times Cited: 4
Yuan Zhang, Jinheng Qian, Yanneng Fu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2024) Vol. 1870, Iss. 7, pp. 167447-167447
Closed Access | Times Cited: 4
SLC2A1 boosts the resistance of non-small cell lung cancer to taxanes by stimulating the formation of EPCAM+ cancer stem-like cells via glycolysis
Zhe Yu, Jian Sun, Kai Fang, et al.
Translational Oncology (2024) Vol. 49, pp. 102082-102082
Open Access | Times Cited: 4
Zhe Yu, Jian Sun, Kai Fang, et al.
Translational Oncology (2024) Vol. 49, pp. 102082-102082
Open Access | Times Cited: 4
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Ming Gao, Xia Zhang, Huan Yan, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Transformation of lung adenocarcinoma to small cell lung cancer following osimertinib treatment: a case report and literature review
Linwu Kuang, Peng Wang, Lin Zhou, et al.
Anti-Cancer Drugs (2025)
Open Access
Linwu Kuang, Peng Wang, Lin Zhou, et al.
Anti-Cancer Drugs (2025)
Open Access
SMR-guided molecular subtyping and machine learning model reveals novel prognostic biomarkers and therapeutic targets in non-small cell lung adenocarcinoma
Baozhen Wang, Yichen Yin, Anqi Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Baozhen Wang, Yichen Yin, Anqi Wang, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy(2006-present)
Yufeng An, Xinya Lv, Shidi Xu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117268-117268
Closed Access
Yufeng An, Xinya Lv, Shidi Xu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117268-117268
Closed Access
Development and validation of an ultrasensitive qPCR method to identify and quantify EGFR T790M in cell-free DNA
Shaoji Yuan, Nan Jia, Guofu Lu, et al.
Bioanalysis (2025) Vol. 17, Iss. 1, pp. 49-62
Closed Access
Shaoji Yuan, Nan Jia, Guofu Lu, et al.
Bioanalysis (2025) Vol. 17, Iss. 1, pp. 49-62
Closed Access
Rare skin adverse reactions induced by osimertinib: a case report and literature review
Ye Zhang, Mathew Ling, Min Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Ye Zhang, Mathew Ling, Min Wang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Review on Pharmaceutical Industries Production of Medicines for Lung Cancer Diseases Prevention and Side Effects DataSets View and Analysis with Orange Software Visualization Techniques
V. Srinivasan, S. Soumya
International Journal of Management Technology and Social Sciences (2025), pp. 17-44
Open Access
V. Srinivasan, S. Soumya
International Journal of Management Technology and Social Sciences (2025), pp. 17-44
Open Access
Possible new mechanisms of primary drug resistance in NSCLC with EGFR mutation treated with Osimertinib
Lujing Shao, Tong Li, Xinyan Jia, et al.
IUBMB Life (2025) Vol. 77, Iss. 2
Open Access
Lujing Shao, Tong Li, Xinyan Jia, et al.
IUBMB Life (2025) Vol. 77, Iss. 2
Open Access
Huang-qin decoction increases the sensitivity of EGFR-TKIs to NSCLC cells by regulating stat3/GPX4 to induce redox ratio and ROS to inhibit CSCs
Yaya Yu, Chenjing Lei, Yanan Li, et al.
Journal of Traditional and Complementary Medicine (2025)
Open Access
Yaya Yu, Chenjing Lei, Yanan Li, et al.
Journal of Traditional and Complementary Medicine (2025)
Open Access
Characterization and Identification of the Metabolites of Tuxobertinib in Rat, Dog, Monkey, and Human Liver Microsomes by Liquid Chromatography Combined With High Resolution Mass Spectrometry
Pei Liu, Jing Huang, Yao Zhao, et al.
Biomedical Chromatography (2025) Vol. 39, Iss. 3
Closed Access
Pei Liu, Jing Huang, Yao Zhao, et al.
Biomedical Chromatography (2025) Vol. 39, Iss. 3
Closed Access
Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring EGFR 21L858R mutation
Yan’e Liu, Lu Chen, Xin Zhu, et al.
Global Medical Genetics (2025), pp. 100051-100051
Open Access
Yan’e Liu, Lu Chen, Xin Zhu, et al.
Global Medical Genetics (2025), pp. 100051-100051
Open Access
Dual-Targeting TrxR-EGFR Alkynyl-Au(I) Gefitinib Complex Induces Ferroptosis in Gefitinib-Resistant Lung Cancer via Degradation of GPX4
Lingling Wang, Xiaoyan Ma, Ling Zhou, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Lingling Wang, Xiaoyan Ma, Ling Zhou, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
EGFR tyrosine kinase inhibitor ZZC4 overcomes acquired resistance to gefitinib
Mawusse K.I. Attiogbe, Ting‐Ting Huang, Hong-Yi Zhao, et al.
Toxicology and Applied Pharmacology (2025), pp. 117280-117280
Closed Access
Mawusse K.I. Attiogbe, Ting‐Ting Huang, Hong-Yi Zhao, et al.
Toxicology and Applied Pharmacology (2025), pp. 117280-117280
Closed Access
Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors
Ching‐Yi Lee, Shih‐Wei Lee, Yi‐Chiung Hsu
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2042-2042
Open Access
Ching‐Yi Lee, Shih‐Wei Lee, Yi‐Chiung Hsu
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2042-2042
Open Access
From Mechanisms to Therapeutics: Tackling Resistance in EGFR, KRAS, and ALK in NSCLC
Hongyu Liu
Highlights in Science Engineering and Technology (2025) Vol. 129, pp. 194-201
Closed Access
Hongyu Liu
Highlights in Science Engineering and Technology (2025) Vol. 129, pp. 194-201
Closed Access
Comprehensive analysis of the potential mechanism of gansui in blocking non-small cell lung cancer progression
Xiaoxu Yang, Wenlan Li
Pharmaceutical Biology (2025) Vol. 63, Iss. 1, pp. 170-187
Open Access
Xiaoxu Yang, Wenlan Li
Pharmaceutical Biology (2025) Vol. 63, Iss. 1, pp. 170-187
Open Access
Efficient evaluation of osteotoxicity and mechanisms of endocrine disrupting chemicals using network toxicology and molecular docking approaches: triclosan as a model compound
Zhongyuan Wang, Jian Wang, Qiang Fu, et al.
Ecotoxicology and Environmental Safety (2025) Vol. 293, pp. 118030-118030
Open Access
Zhongyuan Wang, Jian Wang, Qiang Fu, et al.
Ecotoxicology and Environmental Safety (2025) Vol. 293, pp. 118030-118030
Open Access
A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Chandrakant Gawli, Chandragouda R. Patil, Harun Patel
Bioorganic & Medicinal Chemistry (2025) Vol. 123, pp. 118146-118146
Closed Access
Chandrakant Gawli, Chandragouda R. Patil, Harun Patel
Bioorganic & Medicinal Chemistry (2025) Vol. 123, pp. 118146-118146
Closed Access
